Data demonstrates safety and efficacy of robotic-assisted percutaneous coronary interventions, while enhancing control and radiation protection for interventional cardiologists
NATICK, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that the CorPath® PRECISE Trial has been selected as a late breaking clinical trial at The Society for Cardiovascular Angiography and Interventions’ (SCAI) Scientific Sessions. Dr. Giora Weisz, director of Clinical Cardiovascular Research at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and the co-principal investigator of the trial will present data demonstrating that its CorPath® 200 System can safely assist interventional cardiologists in performing percutaneous coronary interventions (PCI) procedures. The presentation will take place on Thursday, May 10 at 12:13 p.m. in room MEC B at Mirage Hotel and Convention Center in Las Vegas.
“This study has the potential to transform the way interventional cardiologists will perform PCI procedures,” said Dr. Weisz. “Data from the CorPath PRECISE Trial has demonstrated the safety and efficacy of robotic-assisted PCI procedures in a large multi-center study. Additionally, the study demonstrated the CorPath 200 System provides physicians with additional control and significant protection against harmful radiation exposure.”
The CorPath 200 System allows interventional cardiologists to perform PCI procedures in a comfortable seated position in a radiation-protected cockpit. In addition to providing an optimal view of the monitors, physicians utilize a joystick to perform precise robotic-assisted placements of coronary guidewires and stent/balloon catheters.
“According to recent data, the high level of radiation and the physical stresses of the cath lab can result in an interventional cardiologist’s development of orthopedic problems, cataracts and cancer,” said J. Jeffrey Marshall, M.D., FSCAI of the Northeast Georgia Heart Center and investigator of the trial. “The CorPath 200 System addresses a need to provide better radiation protection for physicians, while enhancing the precision and control of stent and guidewire positioning—this has the potential to ultimately enhance patient care.”
“We are honored to be selected as one of SCAI’s late breaking clinical trials,” said David M. Handler, President and CEO of Corindus. “We believe the results of the CorPath PRECISE trial demonstrate the technology’s potential to transform the standard of care, and provide interventional cardiologists the ability to improve the health and safety of the cath lab. The feedback from our investigators and the recognition from the society further support our progress.”
To learn more about the CorPath 200 System or reserve hands-on demonstrations of the CorPath 200 System at booth 520, please call 508.653.3335 x200 or email [email protected].
About Corindus Vascular Robotics
Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions. The Company’s CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation shielded interventional cockpit. The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications. Additional information can be found at: http://www.corindus.com
NOTE: The CorPath 200 System is an investigational device and limited by federal law to investigational use only.
KEYWORDS: United States North America Nevada
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Other Health Research Science